康哲药业(China Medical System Holdings Limited)近日宣布,其创新药物CMS-D002针对子宫肌瘤适应症的临床试验申请已获得相关部门批准。
这一批准标志着CMS-D002在子宫肌瘤治疗领域的研发进程取得重要进展,为该创新药物的临床开发奠定了基础。
康哲药业(China Medical System Holdings Limited)近日宣布,其创新药物CMS-D002针对子宫肌瘤适应症的临床试验申请已获得相关部门批准。
这一批准标志着CMS-D002在子宫肌瘤治疗领域的研发进程取得重要进展,为该创新药物的临床开发奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.